tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Manzanares C et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. 1998 Transplant. Proc. pmid:9636513
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Frei U and Wagner K Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. 1994 Transplant. Proc. pmid:7527963
Abou-Jaoude MM et al. Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients. 2003 Transplant. Proc. pmid:14612103
Park K et al. Efficacy of tacrolimus in primary kidney transplant patients: multicenter, open-label prospective study. 2000 Transplant. Proc. pmid:11119901
Lane BC et al. Evaluation of calcineurin's role in the immunosuppressive activity of FK 506, related macrolactams, and cyclosporine. 1993 Transplant. Proc. pmid:7679829
Yu L et al. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation. 2000 Transplant. Proc. pmid:11119902
Christians U et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. 1991 Transplant. Proc. pmid:1721262
Regazzi MB et al. Interaction between FK 506 and diltiazem in an animal model. 1996 Transplant. Proc. pmid:8623215
Ma A et al. Immunological evaluation of combination therapy with tacrolimus and sirolimus on long-term allograft survival in nonhuman primates. 2005 Jan-Feb Transplant. Proc. pmid:15808578
Rahamimov R et al. Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol. 2003 Transplant. Proc. pmid:12644082
Wasserberg N et al. Tacrolimus does not upregulate mucin gene expression after small bowel transplantation in rats. 2003 Transplant. Proc. pmid:12644089
Sgrosso JL et al. Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine. 2002 Transplant. Proc. pmid:11959214
Alarcón-Zurita A et al. Steroids withdrawal after 3 months of successful renal transplantation using a tacrolimus- and mycophenolate-based immunosuppression. 2002 Transplant. Proc. pmid:11959216
Rudich SM et al. Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. 1998 Transplant. Proc. pmid:9636574
Pratschke J et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results. 1998 Transplant. Proc. pmid:9636575
Imamura M et al. FK 506 inhibits severe graft-versus-host disease without mediating cytokine balance and/or cytotoxic molecules. 2000 Transplant. Proc. pmid:11120238
Serrano M et al. Clinical value of a single determination of intracellular ATP levels in stimulated CD4+ T lymphocytes in pediatric patients with stable liver transplantation. 2012 Transplant. Proc. pmid:23146475
Díaz-Molina B et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. 2012 Transplant. Proc. pmid:23146479
Forsythe J Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group. 1999 Transplant. Proc. pmid:10576049
Liu M et al. C4d-positive acute humoral renal allograft rejection: rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil. 2004 Transplant. Proc. pmid:15518760
Ullman KS et al. Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. 1991 Transplant. Proc. pmid:1721294
Yang S et al. Characteristics of long-term immunosuppressive therapy in Chinese pediatric renal transplant patients: a single-center experience. 2009 Transplant. Proc. pmid:20005361
Seymen P et al. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters. 2009 Transplant. Proc. pmid:20005364
Nassar CA et al. Effects of long-term FK 506 therapy on the alveolar bone and cementum of rats. 2009 Transplant. Proc. pmid:19545747
Karabulut AB and Ara C Melatonin ameliorates tacrolimus (FK-506)'s induced immunosupressive effect in rat liver. 2009 Transplant. Proc. pmid:19545748
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Marente VC et al. Modigraf administration through jejunostomy in liver transplant recipient: case report. 2013 Transplant. Proc. pmid:24314992
Niederstadt C et al. Effect of FK506 on magnesium homeostasis after renal transplantation. 1997 Transplant. Proc. pmid:9365709
Vischi S et al. The maltose absorption test does not predict allograft rejection of small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518143
Moscicka M et al. The effect of cyclosporine and tacrolimus on indigenous bacterial flora in human skin grafts. 2003 Transplant. Proc. pmid:14529942
Bahra M et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. 2005 Transplant. Proc. pmid:15919436
Kuriata-Kordek M et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. 2003 Transplant. Proc. pmid:14529944
Ricordi C et al. Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. 1992 Transplant. Proc. pmid:1376512
Vargas V et al. Alpha-interferon for acute hepatitis C in liver transplant patients. 1995 Transplant. Proc. pmid:7533374
Kim HC et al. Primary immunosuppression with tacrolimus in renal transplantation: a single center experience. 2003 Transplant. Proc. pmid:12591370
Hisanaga M et al. Successful combination therapy with FK 506 and 15-deoxyspergualin in pancreatic islet xenografting. 1992 Transplant. Proc. pmid:1376513
Cooper MH et al. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. 1991 Transplant. Proc. pmid:1721326
Maes BD and Vanrenterghem YF Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus. 2004 Transplant. Proc. pmid:15041305
Didlake R and Grogan J Effect of FK 506 on rat leukocyte chemotaxis. 1991 Transplant. Proc. pmid:1721327
Ã…berg F et al. Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report. 2015 Transplant. Proc. pmid:26680092
Malireddy SR et al. Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report. 2008 Transplant. Proc. pmid:18589198
Chen JW et al. Ten-year results of a randomised prospective study of FK506 versus cyclosporine in management of primary orthotopic liver transplantation. 2002 Transplant. Proc. pmid:12176460
Costa A et al. Small bowel myoelectrical activity after transplantation in pigs: motility versus ACR score. 1997 Transplant. Proc. pmid:9142281
Chmiel B et al. Rheological properties of red blood cells in kidney transplant recipients: the role of lipid profile and type of immunosuppresion. 2005 Transplant. Proc. pmid:15919493
Prasad GV et al. Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression. 2005 Transplant. Proc. pmid:15919496
Sakamoto K et al. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. 1995 Transplant. Proc. pmid:7533434
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. 1991 Transplant. Proc. pmid:1721358
Barten MJ et al. Pharmacodynamics of the immunosuppressive effects of the combination of tacrolimus with mycophenolate mofetil. 2002 Transplant. Proc. pmid:12270442
Nalesnik MA et al. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. 1991 Transplant. Proc. pmid:1703335
Yoshimura N et al. Safety analysis following tacrolimus immunosuppression in renal transplant recipients in Japan: 3-year results in over 1000 patients. 2002 Transplant. Proc. pmid:12176501
Takahashi K et al. Successful results after 3 years' tacrolimus immunosuppression in ABO-incompatible kidney transplantation recipients in Japan. 2002 Transplant. Proc. pmid:12176502
Malaise J et al. Immunosuppressive drugs after simultaneous pancreas-kidney transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182827
Zmonarski SC et al. Lowering of Messenger Ribonucleic Acid Toll-Like Receptors 2-4,9 in Peripheral Blood Mononuclear Cells in Kidney Allograft Recipients, Relationships With Immunosuppressive Treatment, and Delayed Graft Function Occurrence. 2016 Transplant. Proc. pmid:27496439
Hung CM et al. Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan. 1998 Transplant. Proc. pmid:9838572
Cheng HM et al. Primary prophylaxis with tacrolimus in kidney transplants in China. 1998 Transplant. Proc. pmid:9838573
Miller J Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 1999 Feb-Mar Transplant. Proc. pmid:10083106
Undre NA et al. Low systemic exposure to tacrolimus correlates with acute rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083114
Busuttil RW and Holt CD Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123119
Gavlik A et al. Mycophenolate mofetil rescue therapy in liver transplant recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123124
Namieno T and Uchino J Comparative study of the effects of cyclosporine and FK 506 on rat hepatocytes cocultured with nonparenchymal liver cells. 1996 Transplant. Proc. pmid:8908147
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Doi R et al. Mechanisms by which FK 506 affects exocrine pancreas in rats. 1991 Transplant. Proc. pmid:1721392
Han DJ et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. 2012 Transplant. Proc. pmid:22310592
Bilbao I et al. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation. 2001 Transplant. Proc. pmid:11377472
van Duijnhoven EM et al. Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. 2002 Transplant. Proc. pmid:12176552
Park JW et al. Invasive pulmonary aspergillosis after living donor liver transplantation should be eradicated or not? A case report. 2011 Jul-Aug Transplant. Proc. pmid:21839284
Chang HR et al. Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients. 2007 Transplant. Proc. pmid:17580178
Weinbroum AA et al. Lack of cumulative effect of tacrolimus and low flow on a rat isolated liver. 2001 Transplant. Proc. pmid:11543812
Zuckermann A et al. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083518
Canivet C et al. T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus. 2008 Transplant. Proc. pmid:19100403
Ohdan H et al. Prolongation of hamster-to-rat liver xenograft survival by donor bone marrow augmentation. 1997 Feb-Mar Transplant. Proc. pmid:9123589
Mabuchi M et al. Insulin-like growth factor-I enhances choleretic action of FK506 in rats. 2003 Transplant. Proc. pmid:12826230
Cooper MH et al. Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. 1991 Transplant. Proc. pmid:1721421
Yoshida Y et al. Effect of lipoprostaglandin E1 in concordant xenografts. 1996 Transplant. Proc. pmid:8658716
McLaughlin GE et al. Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. 2000 Transplant. Proc. pmid:10812158
Levy GA Neoral use in the liver transplant recipient. 2000 Transplant. Proc. pmid:10814745
Tahir W et al. Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation. Transplant. Proc. pmid:25645795
Lo A et al. Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients. 2003 Transplant. Proc. pmid:12742477
Russ GR et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. 2003 Transplant. Proc. pmid:12742480
El-Sabrout R et al. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients. 2002 Transplant. Proc. pmid:12176636
Ciancio G et al. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. 2002 Transplant. Proc. pmid:12176637
Kovarik JM et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. 2006 Transplant. Proc. pmid:17175302
Moura Neto A et al. Clinical Profile of Patients With Diabetes Mellitus and Liver Transplantation: Results After a Multidisciplinary Team Intervention. 2018 Transplant. Proc. pmid:29661438
Wu M et al. Cyclosporine and tacrolimus alter renin-angiotesin system in mouse medullary-thick ascending limb cultured cells. 2001 Feb-Mar Transplant. Proc. pmid:11267198
Luke PP et al. IVIG rescue therapy in renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267206
Halloran PF et al. Calcineurin and the biological effect of cyclosporine and tacrolimus. 1998 Transplant. Proc. pmid:9723430
Walgenbach KJ et al. Upregulation of basic fibroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506. 1998 Transplant. Proc. pmid:9745501
Murio JE et al. Compassionate use of FK 506 in liver transplantation. 1995 Transplant. Proc. pmid:7544501
Chamienia A et al. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results. 2014 Transplant. Proc. pmid:25380901
Sainsbury TS et al. Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. 1991 Transplant. Proc. pmid:1721453
Kocak H et al. Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose. 2005 Transplant. Proc. pmid:16213288
Abou-Jaoude MM et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients. 2005 Transplant. Proc. pmid:16213293
Jordan ML et al. Steroid withdrawal for pancreas transplants under tacrolimus immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267456
Abe T et al. Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation. 2014 Transplant. Proc. pmid:24767367
Li S et al. Intrathymic inoculation of donor bone marrow at the time of transplantation plus a short course of tacrolimus induce long-term acceptance to rat lung allografts. 1998 Transplant. Proc. pmid:9636431
Starzl TE et al. Notes on FK 506. 1991 Transplant. Proc. pmid:1714647
Miyagawa S et al. Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. 1991 Transplant. Proc. pmid:1703687
Carroll PB et al. Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. 1991 Transplant. Proc. pmid:1703688
Pridöhl O et al. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. 2001 Nov-Dec Transplant. Proc. pmid:11750384